ArticleLeukemia2009
A novel pedigree with heterozygous germline RUNX1 mutation causing familial MDS-related AML: can these families serve as a multistep model for leukemic transformation?
Article in Leukemia, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 41 citations in OpenAlex.
- Germline and somatic genetic landscape of pediatric myelodysplastic syndromes.Haematologica · 2025Review
- Germline and somatic drivers in inherited hematologic malignancies.Frontiers in oncology · 2023Review
- Beyond PathogenicCancers · 2022Review
- Adult-onset hereditary myeloid malignancy and allogeneic stem cell transplantation.Frontiers in oncology · 2022Review
- Review of guidelines for the identification and clinical care of patients with genetic predisposition for hematological malignancies.Familial cancer · 2021Review
- Zebrafish Cancer Predisposition Models.Frontiers in cell and developmental biology · 2021Review
- RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML.Blood advances · 2020Article
- The clinical heterogeneity ofResearch and practice in thrombosis and haemostasis · 2020Article
- Monitoring and treatment of MDS in genetically susceptible persons.Hematology. American Society of Hematology. Education Program · 2019Article
- C-terminal RUNX1 mutation in familial platelet disorder with predisposition to myeloid malignancies.International journal of hematology · 2018Article
- [Genetic predisposition to childhood cancer].Der Pathologe · 2018Review
- Genes at the Crossroad of Primary Immunodeficiencies and Cancer.Frontiers in immunology · 2018Review
- Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation.Haematologica · 2017Article
- Myeloid neoplasms with germline DDX41 mutation.International journal of hematology · 2017Review
- Role of RUNX1 in hematological malignancies.Blood · 2017Review
- Clinical utility gene card for: Familial platelet disorder with associated myeloid malignancies.European journal of human genetics : EJHG · 2016Article
- Detection of an Abnormal Myeloid Clone by Flow Cytometry in Familial Platelet Disorder With Propensity to Myeloid Malignancy.American journal of clinical pathology · 2016Article
- Two novel RUNX1 mutations in a patient with congenital thrombocytopenia that evolved into a high grade myelodysplastic syndrome.Leukemia research reports · 2015Article
- A role for RUNX1 in hematopoiesis and myeloid leukemia.International journal of hematology · 2013Review
- Familial aggregation of acute myeloid leukemia and myelodysplastic syndromes.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.